Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model
| Autor: | Altug Yavasoglu, Levent Akman, Teksin Çirpan, Ismet Hortu, Elmin Eminov, Oytun Erbaş |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Agonist medicine.medical_specialty medicine.drug_class medicine.medical_treatment Ovariectomy Osteoporosis 030209 endocrinology & metabolism Rats Sprague-Dawley 03 medical and health sciences 0302 clinical medicine Bone Density Internal medicine medicine Animals Humans Osteoporosis Postmenopausal Bone mineral business.industry Interleukin-6 Tumor Necrosis Factor-alpha Obstetrics and Gynecology Interleukin General Medicine medicine.disease Rats Trabecular bone 030104 developmental biology Cytokine Endocrinology Ovariectomized rat Cytokines Exenatide Female business medicine.drug |
| Zdroj: | Archives of gynecology and obstetrics. 297(6) |
| ISSN: | 1432-0711 |
| Popis: | The aim of this study is to investigate effects of exenatide (Glucagon-Like Peptide Agonist) replacement on bone mineral density (BMD) and microarchitecture in a surgical menopause-induced osteoporosis model in rats. In this study, 24 female Sprague–Dawley albino mature rats were used. Rats were assigned either to the group ovariectomized administered exenatide or to the control group. Bone Mineral Density (BMD), plasma cytokine levels and histomorphometric analysis were measured. Ovariectomized rats showed significant decrease BMD values, trabecular counts, trabecular thickness and trabecular area. Also, significant increase trabecular separation and plasma TNF-α (Tumor Necrosis Factor) and IL-6 (Interleukin) levels. Exenatide treatment reversed these changes and it showed a considerable protective effect on trabecular bone microarchitecture. Exenatide may be a candidate for use in the treatment of postmenopausal osteoporosis and anti-inflammatory properties can be attributed this effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink